Peptide extended insulins
US-9260501-B2 · Feb 16, 2016 · US
Fusion proteins
US9855318B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9855318-B2 |
| Application number | US-201615140519-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2016 |
| Priority date | May 7, 2015 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
First claim
Opening claim text (preview).
We claim: 1. A homodimer of two fusion proteins of having the amino acid sequence of SEQ ID NO: 12. 2. A pharmaceutical composition comprising the homodimer of claim 1 . 3. A method of treating a patient with diabetes mellitus comprising administering to a patient in need thereof the homodimer of claim 1 . 4. A fusion protein having the amino acid sequence of SEQ ID NO: 12.
Assignees
Inventors
Classifications
for hyperglycaemia, e.g. antidiabetics · CPC title
for increasing or potentiating the activity of insulin · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
- A61K38/28Primary
Insulins · CPC title
- C07K14/62Primary
Insulins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9855318B2 cover?
- The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification A61K38/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).